SCHEMBL4422966

SCHEMBL4422966

NC(=O)c1ccc2[nH]c(=O)[nH]c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 2/20 0.60
BCOR Q6W2J9 2/20 0.60
SMYD3 Q9H7B4 1/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
PKM P14618 1/20 0.47
PARP1 P09874 1/20 0.46
MAPT P10636 3/20 0.45
KDM4E B2RXH2 3/20 0.45
LMNA P02545 1/20 0.45
CHEK2 O96017 2/20 0.44
MAPK1 P28482 1/20 0.44
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
GRIK3 Q13003 1/20 0.43
GRIA1 P42261 1/20 0.43
CACNG8 Q8WXS5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29511878 1.00 BCL6 (0.60) BCL6BCORSMYD3MEN1KMT2A
Formic Acid SCHEMBL31473449 0.93 BCL6 (0.55) BCL6BCORSMYD3MEN1KMT2A
Trifluoroacetic Acid SCHEMBL31473352 0.88 BCL6 (0.51) BCL6BCORSMYD3MEN1KMT2A
SCHEMBL3260502 0.82 PARP1 (0.60) BCL6BCORMEN1KMT2AGAA
SCHEMBL29935457 0.82 PARP1 (0.60) BCL6BCORMEN1KMT2AGAA
SCHEMBL1095502 0.82 SIRT2 (0.69) BCL6BCORSMYD3MEN1KMT2A
SCHEMBL3662018 0.81 GRIA1 (0.54) BCL6BCORMEN1KMT2APARP1
SCHEMBL14669432 0.80 CHEK2 (0.67) CHEK2PKN1PKN2
SCHEMBL1119917 0.80 MAPT (0.57) SMYD3MEN1KMT2AGAASIRT2
SCHEMBL28431190 0.80 MAPT (0.49) BCL6BCORSMYD3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP claimed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 EP claimed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 EP claimed
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors Merck Sharp & Dohme, LLC (US) 2024-05-07 US claimed
EP-4225739-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-08-16 EP claimed
WO-2022076495-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-04-14 WO claimed
EP-3703682-B1 COMPOSITIONS AND METHODS FOR THE INHIBITION OF PRURITUS US HEALTH (US) 2022-04-13 EP claimed
WO-2024117179-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ALIVEXIS, INC. (JP) 2024-06-06 WO disclosed
CN-116685577-A Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors 默沙东有限责任公司 2023-09-01 CN disclosed
EP-4225739-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-08-16 EP disclosed
WO-2022076495-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-04-14 WO disclosed
EP-2285783-B1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-21 EP disclosed
US-8263597-B2 Indazole compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-11 US disclosed
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 US disclosed
WO-2009134666-A1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 WO disclosed
EP-1628661-A2 MODULATORS OF VR1 RECEPTOR Vertex Pharmaceuticals Incorporated (US) 2006-03-01 EP disclosed
US-20050004133-A1 Modulators of VR1 receptor VERTEX PHARMACEUTICALS INCORPORATED 2005-01-06 US disclosed
WO-2004108133-A2 MODULATORS OF VR1 RECEPTOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-16 WO disclosed
US-6699880-B1 STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-02 US disclosed
EP-1221443-A1 SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-07-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCRL2 BCL6 3084/4885BCOR 2589/4885SMYD3 3047/4885
US-20050004133-A1 Modulators of VR1 receptor TRPV1, TRPV2, TRPV3 BCL6 3533/4885BCOR 2941/4885SMYD3 4253/4885
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, ACAT2 BCL6 1204/4885BCOR 3027/4885SMYD3 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.